Post by
canadafan on Nov 25, 2022 8:45pm
other analysts
This one is quite long
The key phrase
"they expect to be a partnered phase 3 oncolyogy dvelopper by no later than Fh2024"
"No later than"
Meaning, they could announce tomorrow & take 9 months to get things rolling.
Having a prtnership announcment, being partnered & being a phase 3 developper takes time.
https://leedejonesgable.com/wp-content/uploads/ONC_2022_11_15.pdf
From the report
Accordingly, we expect Oncolytics to be a partnered Phase III-stage oncology biologics developer no later than FH124.
Interesting comaprison tables of other compaines
If you want to do very well in biotech, find the most advanced @ the best discount.
ONC fits that well.
Comment by
fox7mf on Nov 26, 2022 5:39am
Analysts can talk about projections and prospective dates until they're blue in the face. Onc added Parsons and Rigby for one reason and analysts aren't privy to what's going on in negotiations. I still think buyout late '22 - early '23.